PYPD
PolyPid Ltd. NASDAQ Listed Jun 26, 2020$4.38
Mkt Cap $44.6M
52w Low $2.44
72.4% of range
52w High $5.12
50d MA $4.38
200d MA $3.96
P/E (TTM)
-2.1x
EV/EBITDA
-2.1x
P/B
6.6x
Debt/Equity
0.2x
ROE
-311.4%
P/FCF
0.0x
RSI (14)
—
ATR (14)
—
Beta
1.46
50d MA
$4.38
200d MA
$3.96
Avg Volume
52.4K
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
18 Hasivim Street · Petah Tikva, L3 4959376 · IL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | AMC | -0.34 | -0.41 | -20.6% | 4.62 | -0.4% | -0.6% | -4.1% | -4.5% | -8.0% | -7.6% | — |
| Nov 12, 2025 | AMC | -0.54 | -0.37 | +31.5% | 3.75 | +0.0% | -4.5% | -4.3% | -2.9% | -2.9% | -4.0% | — |
| Aug 13, 2025 | AMC | -0.53 | -0.78 | -47.2% | 3.49 | +0.3% | -1.7% | -1.1% | +0.6% | +1.1% | +0.3% | — |
| May 14, 2025 | AMC | -0.80 | -0.70 | +12.5% | 2.90 | +1.4% | -1.7% | -5.2% | -3.1% | +0.0% | -3.1% | — |
| Feb 12, 2025 | AMC | -0.90 | -1.13 | -25.6% | 2.97 | +0.3% | -4.7% | -0.7% | -3.4% | -2.4% | +1.0% | — |
| Nov 13, 2024 | AMC | -1.07 | -1.22 | -14.0% | 3.40 | +0.6% | +0.6% | +4.4% | +1.8% | +5.9% | +2.6% | — |
| Aug 14, 2024 | AMC | -1.51 | -1.25 | +17.2% | 3.49 | -2.6% | +3.2% | +7.4% | +1.7% | +2.6% | +1.1% | — |
| May 8, 2024 | AMC | -1.96 | -1.37 | +30.1% | 4.31 | +4.4% | +4.4% | +10.0% | +10.0% | +0.9% | +10.0% | — |
| Feb 14, 2024 | AMC | -2.17 | -3.97 | -82.9% | 6.23 | +1.8% | +1.3% | +2.7% | -15.7% | -14.3% | -12.2% | — |
| Nov 8, 2023 | AMC | -3.62 | -3.40 | +6.1% | 4.18 | +0.5% | -7.7% | -10.3% | -3.6% | -3.8% | -6.7% | — |
| Aug 9, 2023 | AMC | -0.31 | -3.90 | -1158.1% | 10.20 | +6.5% | +2.9% | +2.9% | -3.8% | +5.0% | +0.9% | — |
| May 10, 2023 | AMC | -0.26 | -8.41 | -3134.6% | 12.30 | -0.7% | -4.9% | -11.5% | -12.2% | -17.1% | -14.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.68 | $4.58 | -2.1% | -1.3% | -1.9% | -5.3% | -5.8% | -9.2% |
| Nov 13 | Roth Capital | Maintains | Buy → Buy | — | $3.75 | $3.75 | +0.0% | -4.5% | -4.3% | -2.9% | -2.9% | -4.0% |
| Aug 14 | Craig-Hallum | Maintains | Buy → Buy | — | $3.49 | $3.50 | +0.3% | -1.7% | -1.1% | +0.6% | +1.1% | +0.3% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.42 | $3.38 | -1.2% | +2.0% | +0.3% | +0.9% | +2.6% | +3.2% |
| Jun 18 | Roth Capital | Maintains | Buy → Buy | — | $3.53 | $3.52 | -0.3% | -6.2% | -7.1% | +4.2% | +1.4% | +5.9% |
| Jun 17 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.67 | $3.57 | -2.7% | -3.8% | -9.8% | -10.6% | +0.3% | -2.5% |
| Jun 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.27 | $3.79 | +15.9% | +2.8% | +7.0% | +5.8% | +4.9% | +4.3% |
| Apr 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.48 | $2.57 | +3.6% | +2.8% | +8.9% | +10.9% | +10.5% | +10.9% |
| Dec 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.97 | $2.83 | -4.7% | -4.0% | -2.7% | +6.1% | +2.4% | +2.7% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.61 | $2.62 | +0.4% | -6.9% | -4.2% | +10.0% | +34.1% | +23.4% |
| Oct 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.55 | $3.45 | -2.8% | -2.8% | -0.3% | +1.1% | -0.3% | -0.3% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.49 | $3.40 | -2.6% | +3.2% | +7.4% | +1.7% | +2.6% | +1.1% |
| Jun 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.18 | $4.20 | +0.5% | -1.7% | -4.3% | +1.9% | -4.8% | -7.2% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.31 | $4.50 | +4.4% | +4.4% | +10.0% | +10.0% | +0.9% | +10.0% |
| May 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.77 | $5.05 | +5.9% | +4.8% | +0.6% | +3.6% | +3.6% | +1.9% |
| Oct 23 | Barclays | Maintains | Equal Weight → Equal Weight | — | $3.77 | $3.88 | +2.9% | +3.7% | +0.5% | +2.4% | -1.9% | +0.3% |
| Sep 7 | Barclays | Downgrade | Overweight → Equal Weight | — | $34.50 | $34.80 | +0.9% | +4.3% | -4.3% | -6.1% | +48.7% | +20.9% |
| Sep 6 | Raymond James | Downgrade | Strong Buy → Outperform | — | $42.90 | $39.30 | -8.4% | -19.6% | -16.1% | -23.1% | -24.5% | +19.6% |
| Aug 11 | BMO Capital | Maintains | Outperform → Outperform | — | $182.25 | $184.20 | +1.1% | -1.2% | -0.6% | +4.5% | +5.3% | +2.9% |
| Feb 11 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $148.50 | $151.80 | +2.2% | +4.0% | +3.4% | -2.0% | -4.0% | -8.3% |
| Sep 14 | JMP Securities | Maintains | Market Outperform → Outperform | — | $223.20 | $225.30 | +0.9% | -0.5% | +3.5% | +2.3% | +4.6% | +4.0% |
| Jul 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $216.90 | $222.60 | +2.6% | +13.0% | +10.4% | +9.5% | +4.3% | +10.5% |
| Aug 10 | Alliance Global Partners | Maintains | Buy → Buy | — | $426.30 | $455.91 | +6.9% | +0.0% | -3.1% | -2.7% | -1.5% | -2.1% |
| Jul 21 | BMO Capital | Maintains | Outperform → Outperform | — | $468.30 | $480.00 | +2.5% | +2.5% | +8.3% | +2.6% | +3.4% | +4.1% |
| Jul 21 | Raymond James | Maintains | Outperform → Outperform | — | $468.30 | $480.00 | +2.5% | +2.5% | +8.3% | +2.6% | +3.4% | +4.1% |
| Jul 21 | Barclays | Maintains | Overweight → Overweight | — | $468.30 | $480.00 | +2.5% | +2.5% | +8.3% | +2.6% | +3.4% | +4.1% |
No insider trades available.
No recent filings available.
Data updated apr 26, 2026 9:22pm
· Source: massive.com